Approach to Multiple Enterocutaneous Fistulas (ECF) - Post-Gastrectomy, Multi-Operated Abdomen

Clinical Context and Risk Stratification

• Total gastrectomy with Roux reconstruction = altered anatomy, compromised vascularity
• Multiple prior laparotomies = dense adhesions, "frozen abdomen" likely
• FJ dislodgement into Roux limb = prior technical complication implying friable tissue
• Multiple fistulas = implies diffuse enterotomy/bowel injury, not a single anastomotic leak
• 2-year post-cancer surgery = must exclude local recurrence as a contributing cause

• Multiple fistula openings ✓
• Hostile abdomen / open wound likely ✓
• Jejunal origin fistulas ✓ (high-output, poor spontaneous closure)
• Probable malnutrition ✓ (total gastrectomy + multiple operations)
• Likely epithelialized tracts (if chronic) ✓
• Possible distal obstruction ✓

The 5-Phase Approach (Evenson & Fischer / Maingot's)

PHASE 1: Recognition and Stabilization (Days 1-5)

• Aggressive IV fluid replacement - ECF output must be measured and replaced ml-for-ml (isotonic saline + KCl)
• Correct electrolyte abnormalities (hyponatremia, hypokalemia, metabolic acidosis)
• Measure fistula output every 8 hours - classify as:
  • Low output: < 200 mL/day
  • Moderate: 200-500 mL/day
  • High output: > 500 mL/day (most small bowel fistulas)

• Blood cultures, urine culture
• CT abdomen with oral + IV contrast - mandatory to map:
  • Number and locations of fistula openings
  • Presence of undrained collections/abscesses
  • Bowel continuity and distal obstruction
  • Exclude local recurrence
• Drain any undrained collections percutaneously (IR-guided) before any surgery
• Targeted antibiotics (cover gram-negatives + anaerobes; consider antifungals if prolonged ICU)
• Critically: do NOT rush to the operating room at this stage

PHASE 2: Investigation and Anatomical Definition

• CT fistulogram (water-soluble contrast via fistula opening): delineates tract, bowel segment of origin, distal obstruction
• Upper GI contrast study (water-soluble): assesses Roux limb continuity, identifies site of leakage relative to esophagojejunal anastomosis
• Sinogram/fistulogram: maps tract length, branching, communication with bowel
• MRI if CT insufficient or radiation concern

• Gastroscopy (or push enteroscopy) to assess esophagojejunal anastomosis, Roux limb integrity
• Rule out recurrent gastric cancer at the anastomosis

• CBC, CMP, albumin, pre-albumin, transferrin, CRP
• Coagulation profile
• Fistula fluid amylase (if pancreatic fistula component suspected)
• Wound swabs for culture

PHASE 3: Nutritional Optimization ("Feed the Patient, Not the Fistula")

• Calculate requirements: 25-35 kcal/kg/day, 1.5-2 g protein/kg/day
• Assess micronutrient deficiencies: Vitamin B12 (critical post-gastrectomy), iron, thiamine, folate, Vitamin D, zinc

• Octreotide/Somatostatin (50-100 mcg SC TID): reduces fistula output, may accelerate closure in high-output fistulas; most evidence in pancreatic fistulas but used routinely
• Proton pump inhibitors: reduce gastric secretion load (less relevant post-gastrectomy, but may help)
• Do NOT use anti-diarrheal agents to falsely reduce output measurements

PHASE 4: Wound Management and Skin Protection

• Protect perifistula skin from enzymatic small bowel effluent (causes severe excoriation)
• Stoma paste + skin barriers (karaya powder, pectin-based wafers) around fistula openings
• Negative Pressure Wound Therapy (NPWT/VAC): highly effective for:
  • Controlling multiple ECF outputs
  • Reducing wound contamination
  • Promoting granulation
  • Managing enteroatmospheric fistulas in open abdomen
  • The 2024 review (PMID 38592102) confirms NPWT as a key modality for complex ECF/EAF management
• Enterostomal therapy nurse involvement is mandatory

• Individual fistula isolation with pouching systems where possible
• Allows quantification of individual fistula outputs
• Reduces nursing burden and improves patient dignity/QoL

PHASE 5: Definitive Surgical Repair

• Sepsis controlled (no undrained collections, afebrile, inflammatory markers normalizing)
• Nutrition optimized (albumin > 30 g/L, pre-albumin > 15 mg/dL ideally; weight-stabilized)
• Anatomy defined (complete imaging of fistula tract, bowel continuity, wall anatomy)
• Process resolved (inflammation abated, "hostile abdomen" converted to "safe abdomen")

• Enter abdomen through previously unopened area if possible (typically cephalad or caudad to prior incisions)
• Expect inadvertent enterotomy in ~20% of cases - plan for it, have staplers ready
• Complete adhesiolysis of entire small bowel ("bowel run")
• En bloc resection of fistula-bearing bowel segments with primary anastomosis (not simple fistula closure, which has very high recurrence)
• Abdominal wall reconstruction may require component separation or biologic mesh
• Avoid new foreign material (synthetic mesh) in a contaminated field
• Defunctioning proximal stoma should be considered if anastomotic integrity is in doubt

• The Roux limb anatomy needs to be completely re-mapped - may need reconstruction of the Roux-en-Y configuration
• If bowel length is compromised (multiple resections), intestinal failure/short bowel syndrome must be anticipated
• Consider referral to an intestinal failure unit (IFU) if available

Special Considerations for This Patient

• She is 2 years post-resection for gastric cancer - must confirm no peritoneal recurrence contributing to fistulas
• CT, CEA/CA19-9 if not already done

• D2 total gastrectomy already reduces absorptive surface; multiple small bowel resections risk short gut
• Maintain bowel length aggressively - use primary anastomosis over stoma formation wherever feasible
• Refer to hepatology/intestinal failure service if short bowel becomes a concern

• Vitamin B12: monthly IM injections 1000 mcg (oral absorption abolished)
• Iron: IV iron infusions preferred (no intrinsic factor, poor oral absorption)
• Thiamine, folate, Vitamin D, calcium - routine supplementation

• Multiple fistulas, prolonged hospitalization, and cancer history create severe psychological burden
• Involve psychiatry/psychology and social work early

Summary Algorithm

Multiple ECF, post-gastrectomy, hostile abdomen
         |
Phase 1: RESUSCITATE + control sepsis
         ↓
Drain all collections (IR if possible, avoid OR)
         ↓
Phase 2: DEFINE anatomy (CT fistulogram, upper GI contrast, endoscopy)
         ↓
Phase 3: OPTIMIZE nutrition (TPN ± fistuloclysis, octreotide)
         ↓
Phase 4: WOUND CARE (NPWT, stoma therapy, pouching)
         ↓
Wait 6-12 months if no spontaneous closure
         ↓
Phase 5: DEFINITIVE SURGERY (resection + anastomosis + abdominal wall reconstruction)

Key References

• Maingot's Abdominal Operations - Enterocutaneous Fistula chapter (Table 10-7, Table 10-8, 5-phase management)
• Yamada's Textbook of Gastroenterology - ECF and nutritional support including fistuloclysis
• Rashed AM et al. "Enterocutaneous Fistulas: Current Management." Nutrients 2026 - PMID 42356313 (most current comprehensive review)
• Pepe G et al. "Entero-Cutaneous and Entero-Atmospheric Fistulas: NPWT." J Clin Med 2024 - PMID 38592102

Flucloxacillin - Pediatric Dosing

Oral Dose (weight-based, community standard)

• Standard: 12.5 mg/kg/dose every 6 hours (max 500 mg/dose)
• Severe (e.g., osteomyelitis): 25 mg/kg/dose every 6 hours (max 1 g/dose)

IV / IM Dose (children ≥4 weeks to 18 years)

Key Administration Points

• Give on an empty stomach - 30-60 min before food or 2 hours after (oral absorption reduced by food)
• IV intermittent infusion: dilute in glucose 5% or NaCl 0.9%, give over 30-60 minutes
• Continuous IV infusion is preferred for severe infections (maximizes time-dependent bactericidal effect)

Dose Adjustments

Formulations Available

• Oral suspension: 125 mg/5 mL and 250 mg/5 mL
• Capsules: 250 mg, 500 mg
• IV powder for injection: 250 mg, 500 mg, 1 g vials

Important Cautions in Children

• Hepatotoxicity: rare but can cause severe hepatitis and cholestatic jaundice, especially with prolonged IV courses - monitor LFTs
• Phlebitis: common with peripheral IV; consider PICC/central line for prolonged courses
• Neonates: not routinely recommended in those <4 weeks old (premature or newborn) - refer to neonatal-specific protocols
• Each 1 g vial contains 2.2 mmol sodium - relevant in fluid-restricted patients

Common Indications in Pediatrics

• Skin and soft tissue infections (impetigo, cellulitis, wound infections)
• Osteomyelitis / septic arthritis (high-dose IV then step-down oral)
• Staphylococcal pneumonia
• Neonatal skin infections